After Actuate Therapeutics released positive early trial data for pediatric cancers, leading international research groups initiated contact. They not only wanted to help develop the drug but had already independently tested the molecule, demonstrating how powerful data can attract inbound, high-caliber partnership opportunities.

Instead of immediately releasing functional data to satisfy investors and social media, Solid Biosciences is strategically withholding it. The company will first share the analysis with the FDA to align on an accelerated approval pathway, believing this professional courtesy builds a stronger regulatory relationship and improves the long-term outcome.

While touted for accelerating trials, the initiative's most transformative aspect is forcing sponsors and the FDA to agree on actionable efficacy and safety signals beforehand. This fundamentally shifts the review process from massive data submission to a focused dialogue, enhancing review quality and clarity far more than just improving timelines.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

For regenerative medicines, RMAT designation can be a better regulatory tool, offering more flexibility. However, companies may pursue a dual-designation strategy, later seeking Breakthrough Therapy status primarily for its broader name recognition and signaling value to investors, partners, and payers.

A key employee at Jared Bauer's first company taught him that agencies like the FDA are not enemies. By understanding their goal is to protect patients, he learned to partner with them and proactively address their concerns, a mindset he found highly effective.

Instead of passively waiting for clarity, Almac aggregated common sponsor concerns about new UK trial regulations and presented them to the MHRA. This proactive engagement was "unprecedented" and resulted in the regulator rapidly updating its guidance, demonstrating that a collaborative approach can shape and accelerate regulatory clarification.

An accelerated designation doesn't speed up development on its own. Sponsors who treat it merely as a press release or stock bump leave most of the value on the table. Success requires actively using the designation to engage in early FDA meetings, advance CMC readiness, and lock in endpoints.

MedTech AI companies can speed up regulatory approval by building a trusted, real-time post-market surveillance system. This shifts the burden of proof from pre-market studies to continuous real-world evidence, giving regulators the confidence to approve innovations faster, turning them from blockers into partners.